Contact
searchSearch
HMP Global

Value-Based Care Basic Listing

Industry Insights
News Conference Coverage
Issue Content
Managed Care Q&A

podcasts


Bhat Headshot
Podcasts
Time-Limited Therapy in CLL: A Value-Based Approach to Modern Oncology
07/08/2025
Seema A. Bhat, MD
Dr Seema Bhat explores how fixed-duration therapies are reshaping chronic lymphocytic leukemia (CLL) treatment, offering real-world insight into clinical decision-making, economic impact, and patient quality of life.
Dr Seema Bhat explores how fixed-duration therapies are reshaping chronic lymphocytic leukemia (CLL) treatment, offering real-world insight into clinical decision-making, economic impact, and patient quality of life.
Dr Seema Bhat explores how...
07/08/2025
First Report Managed Care
Larry Hsu Headshot
Podcasts
Expert Insights into Value-Based Care for Polymyalgia Rheumatica
01/11/2024
Larry Hsu, MD
A doctor and expert in value-based care offers insights into treatment costs and treatment regimens for patients with polymyalgia rheumatica.
A doctor and expert in value-based care offers insights into treatment costs and treatment regimens for patients with polymyalgia rheumatica.
A doctor and expert in...
01/11/2024
First Report Managed Care
Podcasts
A Payer's Perspective on Value-Based Care and Treatment Costs for Rheumatic Conditions
11/06/2023
Steven Peskin, MD
Dr Steven Peskin, general internal medicine specialist and CEO of SRP Advisors, joins us today to discuss value-based care and treatment costs for patients with rheumatic conditions.
Dr Steven Peskin, general internal medicine specialist and CEO of SRP Advisors, joins us today to discuss value-based care and treatment costs for patients with rheumatic conditions.
Dr Steven Peskin, general...
11/06/2023
First Report Managed Care
Headshot of John Tesser, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Combining Pegloticase With Methotrexate Bolsters Response Rate in Patients With Chronic Gout
03/02/2023
Maria Asimopoulos
John RP Tesser, MD, rheumatology specialist, Arizona Arthritis & Rheumatology Associates, and clinical adjunct professor, Midwestern University College of Health Sciences, discusses the MIRROR trial, a study which showed the addition of an...
John RP Tesser, MD, rheumatology specialist, Arizona Arthritis & Rheumatology Associates, and clinical adjunct professor, Midwestern University College of Health Sciences, discusses the MIRROR trial, a study which showed the addition of an...
John RP Tesser, MD, rheumatology...
03/02/2023
First Report Managed Care
Headshot of Louis Allesandrine, Otsuka, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Reviewing Autosomal Dominant Polycystic Kidney Disease Burden, Resources
02/03/2023
Maria Asimopoulos
Louis Allesandrine, vice president, commercial franchise head, Nephrology, Otsuka America Pharmaceutical, Inc, offers insight into the prevalence and symptom burden of autosomal dominant polycystic kidney disease (ADPKD), as well as several...
Louis Allesandrine, vice president, commercial franchise head, Nephrology, Otsuka America Pharmaceutical, Inc, offers insight into the prevalence and symptom burden of autosomal dominant polycystic kidney disease (ADPKD), as well as several...
Louis Allesandrine, vice...
02/03/2023
First Report Managed Care
Headshot of Omar Sinno, UCB, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Reviewing Phase 3 Data on a Subcutaneous C5 Inhibitor for Myasthenia Gravis
12/08/2022
Maria Asimopoulos
Omar Sinno, MD, MBA, medical lead, rare disease, UCB, walks through the findings and implications of the phase 3 RAISE study which evaluated zilucoplan for the treatment of patients with myasthenia gravis.
Omar Sinno, MD, MBA, medical lead, rare disease, UCB, walks through the findings and implications of the phase 3 RAISE study which evaluated zilucoplan for the treatment of patients with myasthenia gravis.
Omar Sinno, MD, MBA, medical...
12/08/2022
First Report Managed Care
Norm Smith, Principle Payer Market Research Consultant
Podcasts
Quality Value Proposition Is Key to Improving OAB Care, Coverage for Older Adult Members
04/19/2022
Edan Stanley
Norm Smith, principal payer market research consultant, emphasizes the importance of ensuring market access teams are equipped with quality value propositions which demonstrate the clinical value and cost benefits of overactive bladder...
Norm Smith, principal payer market research consultant, emphasizes the importance of ensuring market access teams are equipped with quality value propositions which demonstrate the clinical value and cost benefits of overactive bladder...
Norm Smith, principal payer...
04/19/2022
First Report Managed Care
Headshot of Gary Owens, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Payers Can Use Clinical, Value Comparison Data for Atopic Dermatitis Therapy
09/24/2021
Edan Stanley
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of...
09/24/2021
First Report Managed Care

Pipeline Projections

Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
Pipeline Projections
Examining Newly FDA-Approved Anticoagulants and Upcoming Drugs in the Approval Pipeline
02/12/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline...
02/12/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use